Early Phase 1 Melanoma Trial, Recruiting NCT07628634 Sponsor: University of California, Irvine Condition: Melanoma
Back to Melanoma

Early Phase 1 Melanoma Trial, Recruiting

NCT07628634
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older.
  • People who have been diagnosed with solid tumours that have spread, come back, or cannot be surgically removed.
  • People with a life expectancy of at least 3 months.
  • People who are well enough to carry out basic daily activities, as measured by a standard medical scale called the ECOG scale (scores 0–2) (confirm with trial site).
  • People whose heart, liver, kidneys, and other organs are functioning adequately, as determined by standard blood tests reviewed by the trial doctor.
  • Women who could become pregnant must have a negative pregnancy test within 7 days before joining the trial, and must agree to use reliable contraception throughout the trial and for 30 days after the last treatment dose.
  • Women considered unable to become pregnant must have a documented history of menopause (at least 1 year without periods), tubal ligation, or hysterectomy.
  • People who are willing and able to follow a special low-methionine diet as set out by the trial protocol (methionine is an amino acid found in many foods).
  • People, or their legally authorised representatives, who provide written informed consent before any trial-related procedures begin.
  • People who are able to receive standard cancer treatment given throughout the body (systemic therapy).

For people with glioma (a type of brain tumour) specifically:

  • People with a confirmed tissue diagnosis of either newly diagnosed grade 2–3 glioma, or recurrent glioma of any grade.
  • People who are able to receive radiation therapy and/or chemotherapy as part of their treatment.

Who may not be able to join:

  • People with brain metastases (cancer that has spread to the brain) that are uncontrolled or causing symptoms. Note: people whose brain metastases have been treated and are not causing symptoms may still be considered eligible, including those who need steroids (confirm with trial site).
  • People with serious uncontrolled illnesses, including active infections needing systemic treatment, severe heart conditions such as a heart attack within the past 6 months, uncontrolled chest pain, serious heart failure, or significant heart rhythm problems, or uncontrolled diabetes.
  • People with serious conditions that affect how the body processes amino acids or absorbs nutrients, including severe liver disease such as cirrhosis, inherited metabolic disorders affecting how the body processes certain amino acids, or severe gut conditions such as active inflammatory bowel disease or short bowel syndrome.
  • People who have had major surgery within 4 weeks before joining the trial (minor procedures such as biopsies may be acceptable at the trial doctor's discretion).
  • People who have another cancer that requires active treatment during the trial or that may interfere with the trial treatment.
  • People who are pregnant or breastfeeding.
  • People with severe malnutrition or significant nutritional deficiencies, as determined by the trial doctor.
  • People with a history of substance abuse or dependency within the past 6 months that, in the trial doctor's opinion, would affect their ability to follow trial requirements.
  • People with chronic kidney disease at an advanced stage (stage 3b or higher).
  • People with psychiatric conditions that would affect their ability to give informed consent or follow trial requirements, as determined by the trial doctor.
  • People with known allergies or intolerances to low-methionine foods.
  • People with any medical or surgical condition that, in the trial doctor's opinion, would make following the low-methionine diet unsafe or not practical.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Zhaohui A Arter, MD, Chao Family Comprehensive Cancer Center

Phone: 877-827-8839

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
University of California, Irvine
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Adherence to Diet

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov